Medications

Repurposed drug shows promise for treating cardiac arrhythmias

Ruxolitinib, a drug that is already approved by the U.S. Food and Drug Administration (FDA) for treating certain cancers and skin conditions, is effective at inhibiting CaMKII, a protein kinase linked to cardiac arrhythmias.

Medical research

How the body responds to exercise at the cellular level

Researchers have long been fascinated by the possibility that exercise causes various cells in our body to produce molecules that benefit human health, says Jonathan Long, assistant professor of pathology at Stanford University.

page 7 from 40